TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04242264

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sterile Normal Saline, USP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei strain 53G
Description: 1.5 x 10\^3 Colony Forming Units (cfu) Shigella sonnei 53G, a virulent strain of wildtype Shigella sonnei

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei strain 53G
Description: 1.5 x 10\^3 Colony Forming Units (cfu) Shigella sonnei 53G, a virulent strain of wildtype Shigella sonnei

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Shigella sonnei strain 53G
Description: 1.5 x 10\^3 Colony Forming Units (cfu) Shigella sonnei 53G, a virulent strain of wildtype Shigella sonnei

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WRSs2
Description: 10\^6 Colony Forming Units (cfu) dose of an oral live-attenuated Shigella sonnei vaccine candidate derived from a virulent S. sonnei strain Moseley (WRSs2)-a live, attenuated vaccine that has been manufactured under cGMP conditions at the WRAIR PBF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WRSs2
Description: 10\^6 Colony Forming Units (cfu) dose of an oral live-attenuated Shigella sonnei vaccine candidate derived from a virulent S. sonnei strain Moseley (WRSs2)-a live, attenuated vaccine that has been manufactured under cGMP conditions at the WRAIR PBF
Study: NCT06122896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening Blood Tests
Description: Carbohydrate antigen (CA) 19-9, Hemoglobin A1C (HbA1c), and Fasting blood glucose (FBG) per standard-of-care.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound
Description: Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Cholangiopancreatography
Description: Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.
Study: NCT05494502

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Prior to general anesthesia, ultrasound guided erector spinae plane block (ESPB; performed with 0.5% ropivacaine 35 ml with dexmedetomidine 1 microgram/kg) is performed at T2 level (15 ml) and T4 level (20 ml).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: General anesthesia alone.
Study: NCT05274113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ultrasound guided supraclavicular block with ropivacaine will be given to patients before surgery
Study: NCT04955548

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic micro-fracture
Description: Surgeons routinely perform international standard micro-fracture surgery to repair cartilage damage
Study: NCT05253313

Intervention type: OTHER
Group type: OTHER
Intervention: MRI scan
Description: Patients will be randomized to a pre-operative scan or not. The MRI scan will evaluate the local extent of the tumor and especially focus on identifying possible liver metastases unseen on the CT-scan.
Study: NCT05985122

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: C3NEF assay
Description: This assay will consist of a dual test, detecting C3 convertase binding C3NEF autoantibodies and measuring the functional consequence by complement alternative pathway (AP) activity using two distinct ELISA designs: C3NEF detection assay and AP activity assay.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: C3NEF assay
Description: This assay will consist of a dual test, detecting C3 convertase binding C3NEF autoantibodies and measuring the functional consequence by complement alternative pathway (AP) activity using two distinct ELISA designs: C3NEF detection assay and AP activity assay.
Study: NCT05739474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine [inactivated]
Description: solution for intramuscular injection, 1 dose (0.5 mL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine [inactivated]
Description: solution for intramuscular injection, 1 dose (0.5 mL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine [inactivated]
Description: solution for intramuscular injection, 1 dose (0.5 mL)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine [inactivated]
Description: suspension for intramuscular and subcutaneous injection, 1 dose (0.5 mL)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine [inactivated]
Description: suspension for intramuscular and subcutaneous injection, 1 dose (0.5 mL)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine [inactivated]
Description: suspension for intramuscular and subcutaneous injection, 1 dose (0.5 mL)
Study: NCT05702307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tagliatella control
Description: Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from tagliatella control, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% sunflower tagliatella
Description: Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 5% sunflower tagliatella, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16% sunflower tagliatella
Description: Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower tagliatella, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16% sunflower penne
Description: Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower penne, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and samples from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16% sunflower fusilli
Description: Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower fusilli, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study: NCT01567683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod (topical use)
Study: NCT04882449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bodyport Scale
Description: The Bodyport scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient's home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF.
Study: NCT06300996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads)
Description: Spinal cord stimulation is FDA approved for treatment of pain. We are proposing utilizing the same technology to help restore motor control in people who have declining function due to the progression of SMA. These are 2-4 leads that are FDA-approved.
Study: NCT05193188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib 12mg per person per day, continuous medication for 2 weeks and 1 week off, 3 weeks 1 cycle, until disease progression or intolerable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anlotinib hydrochloride
Description: Anlotinib 12mg per person per day, continuous medication for 2 weeks and 1 week off, 3 weeks 1 cycle, until disease progression or intolerable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Intravenous injection, once every 3 weeks, until the disease progression or intolerable toxicity
Study: NCT05657041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Body weight adjusted clopidogrel dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Body weight adjusted clopidogrel dosing
Study: NCT06450639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: Satralizumab will be administered SC in the abdominal or femoral region on Day 1, Weeks 2 and 4 (loading doses) and then Q4W from Weeks 8 to 104 (maintenance doses) until the study completion visit.
Study: NCT05479409

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy
Description: radiation therapy combined with chemotherapy prior to surgery
Study: NCT04886999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exploratory study on patient's perception of Asthma symptoms
Description: To assess the perception of symptoms and the psychopharmacological aspects in patients with moderate to severe asthma comparing two inhalers of CHF1535 100/6 µg pMDI
Study: NCT05085795

Intervention type: DEVICE
Intervention: Impulse Oscillometer
Description: The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
Study: NCT05149729

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shortened hip arthroplasty
Description: Crowe type 3 and 4 patients who underwent shortened hip prosthesis
Study: NCT04886999

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exploratory study on patient's perception of Asthma symptoms
Description: To assess the perception of symptoms and the psychopharmacological aspects in patients with moderate to severe asthma comparing two inhalers of CHF1535 100/6 µg pMDI
Study: NCT05010590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romosozumab
Description: Monthly romosozumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romosozumab
Description: Monthly romosozumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Every 6 months denosumab
Study: NCT05228418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Pill
Description: Naltrexone oral bridge to IM naltrexone maintenance therapy
Study: NCT06297148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-management
Description: Patients will have 3-5 sessions with a physiotherapist that include individually tailored education, and address physical, cognitive, and behavioral factors deemed as relevant according to the participant's concerns and challenges. Important aspects in this are: problem-solving, decision-making, resource utilization, therapeutic alliance and taking action (The 5 core skills of self-management). SMART goals and an activity plan between sessions will be used as an exposure to maintain, change, or create health behavior.~Participants will have access to study material, including exercise alternatives and a podcast.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care at the department consists of general information about the condition and advice on pain management and exercise. For further treatment, patients are referred to primary care. Participation in the study will not affect how this is conducted.
Study: NCT05574335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siplizumab
Description: Weekly siplizumab doses for a total of 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siplizumab
Description: Weekly siplizumab doses for a total of 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siplizumab
Description: Weekly siplizumab doses for a total of 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siplizumab
Description: Weekly siplizumab doses for a total of 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siplizumab
Description: Weekly siplizumab doses for a total of 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siplizumab
Description: Weekly siplizumab doses for a total of 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siplizumab
Description: Weekly siplizumab doses for a total of 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siplizumab
Description: Weekly siplizumab doses for a total of 12 weeks
Study: NCT05658354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized cognitive program
Description: BrainHQ was developed by Posit Science and includes computer-based brain-training exercises organized into six categories: Attention, Brain Speed, Memory, People Skills, Intelligence, and Navigation. Participants were instructed to perform a total of 24 sessions of computerized cognitive training at home, consisting of 45 minutes of training, twice per week, over a 3-month period.
Study: NCT05060731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral iron supplementation
Description: Ca. 200-300 mg of ferrous sulfate will be administered orally every day for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous iron supplementation
Description: One dose of intravenous 1000 mg ferric carboxymaltose will be administered on the day of randomization.
Study: NCT01556152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GRC 17536 (Medium Dose)
Description: 1 BD for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GRC 17536 (Low Dose)
Description: 1 BD for 28 Days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo for 28 Days
Study: NCT04975893

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: mRNA-1647
Description: No investigational product will be administered during the Primary Extension Phase or to the participants in the Observational Group.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: mRNA-1647
Description: No investigational product will be administered during the Primary Extension Phase or to the participants in the Observational Group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Description: Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
Study: NCT05414864

Intervention type: DRUG
Group type: OTHER
Intervention: Ramelteon (RozeremR)
Description: 8mg daily

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: sleep hygiene
Description: sleep behavioral guidelines

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: sleep hygiene
Description: sleep behavioral guidelines
Study: NCT06115863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Cognitive Stimulation Interventions
Description: early cognitive stimulation interventions refer to multi-dimensions of stimulative evidenced-based interventions, which are done during the first 24 hours from patient admission to the ICU. They are designed to stimulate cognitive function domains that are impacted by delirium such as attention, registration, recall, and language.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Cognitive Stimulation Interventions
Description: early cognitive stimulation interventions refer to multi-dimensions of stimulative evidenced-based interventions, which are done during the first 24 hours from patient admission to the ICU. They are designed to stimulate cognitive function domains that are impacted by delirium such as attention, registration, recall, and language.
Study: NCT06526221

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine isoniazid testing (IsoScreen test)
Description: Developed by Arkansas' Public Health Service in the 1970s, this test detects metabolites of isoniazid, a drug present in drug-susceptible TB regimens. IsoScreen (GFC Diagnostics, UK) is a commercial version of the Arkansas method with reagents enclosed in a plastic vial, into which 2mL of urine can be injected with a syringe. If the urine contains isoniazid, reagents turn purple/blue (suggesting a dose was taken in the last 24 hours or appropriate adherence) or green (suggesting a dose was taken 24-48 hours before or one missed dose). A yellow result (no color change) suggests medication has not been taken for \>48 hours (two or more missed doses).
Study: NCT05511948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBI-102
Description: Topical application on dorsal hand and upper volar arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Inactive comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroquinone Cream
Description: 4% Hydroquinone cream, Acella (approved), twice daily for 12 weeks
Study: NCT05253040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KEEP Intervention
Description: Educational intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: booklet from Parkinson's UK
Study: NCT06544460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Secondary cytoreduction
Description: Repeated tumor cell reduction surgery for recurrent ovarian cancer patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy
Description: Using the BR-TQR-I intraperitoneal hyperthermic perfusion chemotherapy instrument, after the surgical operation is completed, four drainage tubes are placed in the left and right upper abdomen and lower abdomen respectively. Connect all pipelines and preheat the instrument before starting treatment. The treatment temperature is controlled at 43 ℃± 0.1 ℃, the treatment time is 90 minutes, and the circulation pump flow rate is 400-600ml/min. Within 48 hours after the surgery, cisplatin 75mg/㎡ was added to 3000ml of physiological saline for intraperitoneal hot infusion. Through the comprehensive effects of circulation flushing, hyperthermia, chemotherapy, and thermochemotherapy sensitization, it kills and removes residual cancer cells or small lesions in the abdominal cavity.
Study: NCT06546527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-PSMA-137
Description: \[177Lu\]Lu-PSMA-137 500 MBq;50% optimal dosing;100% optimal dosing
Study: NCT05858814

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC1012 injection (allo-DNT cells)
Description: RC1012 injection (allo-DNT cells) are from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and injected into patients. The drug for this study is an off-the-shelf product. Patients DO NOT need to wait for the cell manufacturing.
Study: NCT05901428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is a deoxyribonucleic acid (DNA) synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin is an antineoplastic agent derived from doxorubicin.Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.
Study: NCT05025267

Intervention type: OTHER
Group type: OTHER
Intervention: Medical Food: Peptide-Based Enteral Formula
Description: Will be fed exclusively the study peptide-based, high protein enteral formula via a feeding tube
Study: NCT05636852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Altropane (123I) Injection
Description: Each subject will receive a single IV administration of 5 mCi (185 MBq) Altropane.
Study: NCT05209412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lepu Paclitaxel coated balloon
Description: Paclitaxel is the pharmacologically active substance for anti-neointima. The active drug coating is located on the surface of the balloon, which contains 1.5 μg Paclitaxel per 1 mm2.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity Zotarolimus eluting stents
Description: The device consists of a balloon-expandable intracoronary drug-eluting stent pre-mounted on the MicroTrac Rapid Exchange stent delivery system. Drug eluting stent is composed of metal stent, primer and drug coating. The Stent is manufactured from a cobalt alloy (MP35N). The strut thickness is 88.9 μm and the length elements is 0.9 mm. The drug coating consists of the zotarolimus and BioLinx polymer (C10/C19/PVP) system. A coating of polymers loaded with zotarolimus in a formulation applied to the entire surface of the stent at a dose of approximately 1.6 µg/mm2 which results in a maximum nominal drug content of 380 µg on the largest stent (4.0 x 38 mm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin is required for 3 months be a part of the dual antiplatelet therapy (DAPT) after PCI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin is required for 3 months be a part of the dual antiplatelet therapy (DAPT) after PCI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI.
Study: NCT05647980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TACTIC
Description: Participants execute the three steps of TACTIC Participants fill in questionnaires Participants take laboratory and biometric tests to measure their cardiovascular risk